MétaCan
Menu
Back to cohort
Record W4413194276 · doi:10.4103/crst.crst_58_25

Nimotuzumab in the treatment of patients with locally advanced HPV-negative oropharyngeal cancer in Indian setting: A health-economic evaluation

2025· article· en· W4413194276 on OpenAlexaff
Vanita Noronha, Vijay Patil, Nandini Menon, Minit Shah, Neera Gupta, Ashish Verma, K Ram Prasanna, Mahendra Rai, Kumar Prabhash

Bibliographic record

VenueCancer Research Statistics and Treatment · 2025
Typearticle
Languageen
FieldMedicine
TopicHead and Neck Cancer Studies
Canadian institutionsEVERSANA (Canada)
Fundersnot available
KeywordsNimotuzumabMedicineOncologyCancerInternal medicine

Abstract

fetched live from OpenAlex

ABSTRACT Background: The addition of nimotuzumab to concurrent chemoradiotherapy (CTRT) has improved outcomes, including progression-free survival (PFS) and overall survival (OS) in human papilloma virus (HPV)-negative oropharyngeal cancers (OPC). Objectives: This study primarily assessed the cost-effectiveness of nimotuzumab plus CTRT versus CTRT alone in HPV(-) OPC in India by estimating the incremental cost-effectiveness ratio (ICER). The secondary objectives included comparing clinical outcomes, including life-years gained and quality-adjusted life years (QALYs), between the two strategies. Materials and Methods: A decision-tree model was developed in Microsoft Excel to assess the cost-effectiveness of nimotuzumab plus CTRT versus CTRT alone for HPV(-) OPC. Health states included locoregional control (LRC), adverse drug events (ADEs), and PFS. The model, from the Indian payer’s perspective, used a 2-year time horizon and applied a 3% annual discount rate. Primary outcomes were ICER and QALYs. Model robustness was confirmed through probabilistic sensitivity analysis (PSA). Results: In the base-case analysis, total costs and QALYs for nimotuzumab plus CTRT versus CTRT alone were ₹9,91,872 versus ₹8,75,180 and 1.262 versus 0.628, respectively. The incremental cost and QALY gain with nimotuzumab were ₹116,692 and 0.634, respectively. The ICER was ₹183,952 per QALY, well below the willingness-to-pay threshold of ₹300,000 per QALY, indicating cost-effectiveness. Net monetary benefit (NMB) and net health benefit (NHB) associated with nimotuzumab were ₹73,508 and 0.245, respectively. Conclusion: Nimotuzumab plus CTRT is a cost-effective option compared with CTRT alone for treating HPV(-) OPC in the Indian healthcare setting.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.670
Threshold uncertainty score0.999

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.049
GPT teacher head0.443
Teacher spread0.394 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueCancer Research Statistics and TreatmentSame topicHead and Neck Cancer StudiesFrench-language works237,207